CEO
Alphageneron Pharmaceuticals
The startup develops unmodified and genetically-modified natural killer (NK) cell therapies to target hematologic cancers and viral infections. By providing allogeneic NK cell therapy and antibodies, the company enhances patients' innate immune response, offering a critical defense against these diseases.
- Biotechnology
Updated 7 months ago
Funding
Raised to date
$250KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops unmodified and genetically-modified natural killer (NK) cell therapies to target hematologic cancers and viral infections. By providing allogeneic NK cell therapy and antibodies, the company enhances patients' innate immune response, offering a critical defense against these diseases.